Bharat Biotech starts phase 3 trials for COVAXIN Covid-19 vaccine

Bharat Biotech starts Phase III trials for COVAXIN.Bharat Biotech’s Phase-3 trials will involve 26,000 volunters from 25 centres in India.It’s the largest clinical trial that will be conducted in India .The volunteers will receive two intramuscular injections in a gap of 28 days.
According to Sushitra Ella , Joint Managing Director of Bharat Biotech “The development and clinical evaluation of COVAXIN™ marks a significant milestone for vaccinology in India, for a novel vaccine. It is important for Indian companies to innovate and develop indigenous vaccines, especially during a pandemic. COVAXIN™ has garnered interest from several countries worldwide for supplies and introduction.”
The 25 centers where phase – 3trials will be conducted are as follows

1. Bhubaneswar IMS SUM hospital
2. New Delhi Guru Tej Bahadur Hospital
3. Mumbai Grant Government Medical College and Sir J.J. Group of Hospitals
4. Guntur Guntur Medical College
5. Bhopal Gandhi Medical College
6. Ahmedabad Gmers Medical College and Civil Hospital
7. Uttar Pradesh Aligarh Muslim University
8. Hyderabad Nizams Institute of Medical Sciences
9. Rohtak Pandit Bhagwat Dayal Sharma University of Health Sciences
10. Goa Redkar Hospital and Research Centre
11. Guwahati institute of medical sciences
12. Faridabad ESIC hospital
13. New Delhi AIIMS
14. Mumbai Lokmanya Tilak Municipal General Hospital And Medical College (Sion Hospital)
15. Nagpur Rahate hospital
16. Patna AIIMS
17. Pondicherry MG Medical College, Sri Balaji Vidyapeeth
18. Bangalore Vydehi institute of medical sciences
19. Vizag King Gorge Hospital
20. Bhopal People’s University
21. Kolkata ICMR-National Institute of Cholera and Enteric Diseases
22. Chennai Directorate of Public Health and Preventive Medicine, Teynampet